Century Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC) on February 26, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Philadelphia, Pennsylvania. The report addresses a regulatory notice regarding the continued listing of its common stock on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing deficiency notice and does not contain financial performance data.
Material Changes and Listing Status
On February 26, 2025, the Company received a "Bid Price Letter" from Nasdaq notifying it of a deficiency under Listing Rule 5450(a)(1). The Company's common stock closing bid price has remained below the minimum requirement of $1.00 per share for the last 31 consecutive business days. This notice is a deficiency alert and does not currently result in delisting or affect trading.
Outlook, Compliance Plan, and Risks
- Compliance Period: The Company has 180 days, until August 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Alternative Path: If compliance is not achieved within the initial 180 days, the Company may transfer to the Nasdaq Capital Market, provided it meets other listing requirements. This would grant an additional 180-day compliance period.
- Management Intent: Management intends to monitor the stock price and consider plans to regain compliance but explicitly states there can be no assurance that compliance will be achieved.
- Risks: Failure to cure the deficiency could lead to delisting. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of future stock price performance.
Key Facts for Investor Verification
- Verify the current closing bid price of IPSC to assess the severity of the deficiency.
- Monitor the Company's stock price trajectory over the next 10 consecutive business days to determine if the initial cure threshold is met.
- Review the Company's most recent periodic filings (10-K or 10-Q) for financial health indicators, as this 8-K contains no financial data.
- Track any future announcements regarding a potential transfer to the Nasdaq Capital Market if the initial 180-day period expires without compliance.